非编码RNA在索拉非尼治疗肝细胞癌耐药中的作用机制

Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma

索拉非尼作为晚期肝细胞癌的一线治疗药物,能够有效改善肝癌患者预后。但索拉非尼耐药已经成为影响肝细胞癌治疗效果的主要障碍。近年来研究发现,非编码RNA在肝细胞癌索拉非尼耐药中起着关键作用。总结了非编码RNA通过诱导肝癌细胞自噬、促进肝癌干细胞增殖、促进肝癌细胞上皮-间质转化过程、抑制肝癌细胞凋亡以及调节肝癌组织微环境来调节肝癌细胞对索拉非尼的敏感性。指出了非编码RNA调控肝细胞癌索拉非尼耐药的分子机制在克服耐药方面的潜在临床意义。

Sorafenib,as the first-line treatment drug for advanced hepatocellular carcinoma(HCC),can effectively improve the prognosis of patients with HCC,but sorafenib resistance has become a major obstacle to the therapeutic outcome of HCC.Recent studies have shown that non-coding RNA plays a key role in sorafenib resistance in HCC.This article summarizes that non-coding RNA regulates the sensitivity of HCC to sorafenib by inducing the autophagy of hepatoma cells,promoting the proliferation of liver cancer stem cells,promoting the EMT process of hepatoma cells,inhibiting the apoptosis of hepatoma cells,and regulating the microenvironment of liver cancer tissue.It is pointed out that the molecular mechanism of non-coding RNA in regulating sorafenib resistance in HCC has potential clinical significance in overcoming sorafenib resistance in HCC.